Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score
Authors:
- Amanda MocroftAMAmanda Mocroft
- Bruno LedergerberBLBruno Ledergerber
- Kai ZilmerKZKai Zilmer
- Ole KirkOKOle Kirk
- Bernard HirschelBHBernard Hirschel
- Jean-Paul ViardJVJean-Paul Viard
- Peter ReissPRPeter Reiss
- Patrick FrancioliPFPatrick Francioli
- Adriano LazzarinALAdriano Lazzarin
- Ladislav MachalaLMLadislav Machala
- Andrew N PhillipsAPAndrew N Phillips
- Jens D LundgrenJLJens D Lundgren
- 1 September 2007
- journal article
- Published by Wolters Kluwer Health in AIDS
- Vol. 21 (14) , 1867-1875
Abstract
To derive and validate a clinically applicable prognostic score for predicting short-term disease progression in HIV-infected patients taking combination antiretroviral therapy (cART). Poisson regression was used to identify prognostic markers for new AIDS/death in patients taking cART. A score was derived for 4169 patients from EuroSIDA and validated on 5150 patients from the Swiss HIV Cohort Study (SHCS). In EuroSIDA, 658 events occurred during 22 321 person-years of follow-up: an incidence rate of 3.0/100 person-years of follow-up [95% confidence interval (CI), 2.7–3.3]. Current levels of viral load, CD4 cell count, CD4 cell slope, anaemia, and body mass index all independently predicted new AIDS/death, as did age, exposure group, a prior AIDS diagnosis, prior antiretroviral treatment and stopping all antiretroviral drugs. The EuroSIDA risk-score was divided into four strata; a patient in the lowest strata would have predicted chance of new AIDS/death of 1 in 801, 1 in 401 and 1 in 201 within the next 3, 6 or 12 months, respectively. The corresponding figures for the highest strata were 1 in 17, 1 in 9 and 1 in 5, respectively. A single-unit increase in the risk-score was associated with a 2.70 times higher incidence of clinical progression (95% CI, 2.56–2.84) in EuroSIDA and 2.88 (95% CI, 2.75–3.02) in SHCS. A clinically relevant prognostic score was derived in EuroSIDA and validated within the SHCS, with good agreement. The EuroSIDA risk-score will be made available publicly via an interface that will perform all calculations for the individual.Keywords
This publication has 30 references indexed in Scilit:
- Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or deathHIV Medicine, 2007
- The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) eraClinical Trials, 2006
- Influence of Hepatitis C Virus Infection on HIV‐1 Disease Progression and Response to Highly Active Antiretroviral TherapyThe Journal of Infectious Diseases, 2005
- Causes of death in HIV infectionAIDS, 2004
- Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 InfectionNew England Journal of Medicine, 2004
- Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy eraAIDS, 2004
- A Clinically Prognostic Scoring System for Patients Receiving Highly Active Antiretroviral Therapy: Results from the EuroSIDA StudyThe Journal of Infectious Diseases, 2002
- Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across EuropeAIDS, 1999
- Changing patterns of mortality across Europe in patients infected with HIV-1The Lancet, 1998
- Long-term survival in patients with advanced immunodeficiencyAIDS, 1997